Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding
نویسندگان
چکیده
منابع مشابه
Paradoxical systemic embolization in hereditary hemorrhagic telangiectasia.
A 53-year-old man presented with sudden onset left-sided weakness. His medical history included hereditary hemorrhagic telangiectasia with recurrent epistaxis. On examination, he was hypoxemic at rest and had left-sided flaccid hemiparesis. He was noted to have multiple lower lip telangiectasias (Figure 1). Computed tomography of chest revealed bilateral segmental and subsegmental pulmonary emb...
متن کاملHereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on the severity and manifestation of the disease, various therapeutic modalities have been used, from local bleeding control to surgery or concomitant drug therapy. Several articles under review have presented guidelines f...
متن کاملBevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indicated for life-threatening disease but carries significant risk from surgery and chronic immunosupp...
متن کاملIs bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
BACKGROUND Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, often manifests with epistaxis. The disease spectrum is wide; some patients have small, irritating bleeds, whereas other patients require monthly blood transfusions. There are many medical and surgical interventions for epistaxis in HHT, but none have been established as a gold-standard treatment. ...
متن کاملBlessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by uncontrolled multisystem angiogenesis with epistaxis, gastrointestinal bleeding, iron-deficiency anemia, and arteriovenous malformations, and is often associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab, a VEGF inhibitor, reduces epistaxis, telangiectasias, and iron-deficien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2016
ISSN: 0361-8609
DOI: 10.1002/ajh.24367